TO CONSULTING AGREEMENT. This Amendment No. 4 to Consulting Agreement (“Amendment No. 4”) is made as of December 18, 2020, by and between Elicio Therapeutics Inc., formerly operating under the name of Vedantra Pharmaceuticals, Inc., with a principal place of business being One ▇▇▇▇▇▇▇ Square, Building 1400 West, Suite 14303, ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ (“Company”) and ▇▇▇▇▇▇▇▇ Advisors, LLC, a Massachusetts limited liability company, with a principal place of business being ▇▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ (“▇▇▇▇▇▇▇▇”). Capitalized terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between ▇▇▇▇▇▇▇▇ and the Company dated as of March 13, 2013 (“Agreement”).
Appears in 1 contract
TO CONSULTING AGREEMENT. This Amendment No. 4 5 to Consulting Agreement (“Amendment No. 4”) is made as of December 18February 1, 20202021, by and between Elicio Therapeutics Inc., formerly operating under the name of Vedantra Pharmaceuticals, Inc., with a principal place of business being One ▇▇▇▇▇▇▇ Square, Building 1400 West, Suite 14303, ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ (“Company”) and ▇▇▇▇▇▇▇▇ Advisors, LLC, a Massachusetts limited liability company, with a principal place of business being ▇▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ (“▇▇▇▇▇▇▇▇”). Capitalized terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between ▇▇▇▇▇▇▇▇ and the Company dated as of March 13, 2013 (“Agreement”).
Appears in 1 contract
TO CONSULTING AGREEMENT. This Amendment No. 4 to Consulting Agreement (“Amendment No. 4”) is made as of December 18, 2020, by and between Elicio Therapeutics Inc., formerly operating under the name of Vedantra Pharmaceuticals, Inc., with a principal place of business being One O▇▇ ▇▇▇▇▇▇▇ Square▇▇▇▇▇▇, Building 1400 West, Suite 14303, ▇▇▇▇▇▇▇▇▇Cambridge, ▇▇ ▇▇▇▇▇ MA 02139 (“Company”) and ▇D▇▇▇▇▇▇▇ Advisors, LLC, a Massachusetts limited liability company, with a principal place of business being ▇9▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ (“▇D▇▇▇▇▇▇▇”). Capitalized terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between ▇D▇▇▇▇▇▇▇ and the Company dated as of March 13, 2013 (“Agreement”).
Appears in 1 contract
TO CONSULTING AGREEMENT. This Amendment No. 4 5 to Consulting Agreement (“Amendment No. 4”) is made as of December 18February 1, 20202021, by and between Elicio Therapeutics Inc., formerly operating under the name of Vedantra Pharmaceuticals, Inc., with a principal place of business being One O▇▇ ▇▇▇▇▇▇▇ Square▇▇▇▇▇▇, Building 1400 West, Suite 14303, ▇▇▇▇▇▇▇▇▇Cambridge, ▇▇ ▇▇▇▇▇ MA 02139 (“Company”) and ▇D▇▇▇▇▇▇▇ Advisors, LLC, a Massachusetts limited liability company, with a principal place of business being ▇9▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ (“▇D▇▇▇▇▇▇▇”). Capitalized terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between ▇D▇▇▇▇▇▇▇ and the Company dated as of March 13, 2013 (“Agreement”).
Appears in 1 contract